WO2010151074A3 - Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy - Google Patents

Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy Download PDF

Info

Publication number
WO2010151074A3
WO2010151074A3 PCT/KR2010/004134 KR2010004134W WO2010151074A3 WO 2010151074 A3 WO2010151074 A3 WO 2010151074A3 KR 2010004134 W KR2010004134 W KR 2010004134W WO 2010151074 A3 WO2010151074 A3 WO 2010151074A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
composition
diagnosing cancer
quantum dot
photodynamic therapy
Prior art date
Application number
PCT/KR2010/004134
Other languages
French (fr)
Korean (ko)
Other versions
WO2010151074A2 (en
Inventor
안웅식
배수미
바토그토크흐간트므르
문란영
Original Assignee
주식회사 진코스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 진코스 filed Critical 주식회사 진코스
Publication of WO2010151074A2 publication Critical patent/WO2010151074A2/en
Publication of WO2010151074A3 publication Critical patent/WO2010151074A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

The present invention relates to a photosensitizer containing conjugates of quantum dot-chlorine derivatives and a composition for treating and diagnosing cancer containing the same for photodynamic therapy. The conjugates of the present invention can be used as a single medicine for treating and diagnosing cancer.
PCT/KR2010/004134 2009-06-26 2010-06-25 Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy WO2010151074A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20090057910 2009-06-26
KR10-2009-0057910 2009-06-26

Publications (2)

Publication Number Publication Date
WO2010151074A2 WO2010151074A2 (en) 2010-12-29
WO2010151074A3 true WO2010151074A3 (en) 2011-05-19

Family

ID=43387066

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/004134 WO2010151074A2 (en) 2009-06-26 2010-06-25 Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy

Country Status (2)

Country Link
KR (1) KR101288460B1 (en)
WO (1) WO2010151074A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2717920A4 (en) * 2011-06-11 2015-04-29 Univ Central Florida Res Found Activatable nanoprobes for intracellular drug delivery
KR101668561B1 (en) 2015-07-13 2016-10-21 원광대학교산학협력단 Composition for photodynamic therapy of cancer diseases using gene expressing green fluorescent protein and rose bengal and method for photodynamic therapy using thereof
US20170049891A1 (en) * 2015-08-17 2017-02-23 Nanoco Technologies Ltd. 5-aminolevulinic acid conjugated quantum dot nanoparticle
RU2638446C1 (en) * 2016-12-14 2017-12-13 федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский ядерный университет МИФИ" (НИЯУ МИФИ) Method for directed destruction of cancer cells
KR101911725B1 (en) 2017-01-16 2018-12-28 주식회사 코어파마 Composition for photodynamic therapy using gene expressing red fluorescent protein and tin ethyl etiopurpurin and method for photodynamic therapy using thereof
CN107722075A (en) * 2017-10-09 2018-02-23 大连理工大学 A kind of chlorin glucoside compounds and preparation method and application
KR102277244B1 (en) * 2019-09-03 2021-07-13 인제대학교 산학협력단 Carbon quantum dots-polypyrrole nano composite for bioimaging and photothermal therapeutics and method for manufacturing the same
KR102294374B1 (en) 2019-09-09 2021-08-26 한국교통대학교산학협력단 Electro Chemical wireless diagnosing method using Carbon quantum dot
KR102256817B1 (en) 2019-09-09 2021-05-26 한국교통대학교산학협력단 Self­Healing Electro Chemical wireless diagnosing method using Hydrogel with Carbon quantum dot
CN114933904B (en) * 2022-06-14 2024-02-06 中国医科大学 Ultrathin shell chiral cadmium selenide/cadmium sulfide material for optical diagnosis and treatment and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080104495A (en) * 2007-05-28 2008-12-03 전남대학교산학협력단 Kits and methods for biological detection using quantum dots

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080104495A (en) * 2007-05-28 2008-12-03 전남대학교산학협력단 Kits and methods for biological detection using quantum dots

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BECHET, DENISE ET AL.: "Nanoparticles as vehicles for delivery of photodynamic therapy agents", TRENDS IN BIOTECHNOLOGY, vol. 26, no. 11, 2008, pages 612 - 621 *
CHO, SUNG JU ET AL.: "Long-Term Exposure to CdTe Quantum Dots Causes Functional Impairments in Live Cells", LANGMUIR, vol. 23, 2007, pages 1974 - 1980 *
SHAN, YAMING ET AL.: "NHS-mediated QDs-peptide/protein conjugation and its application for cell labeling", TALANTA, vol. 75, 2008, pages 1008 - 1014, XP022624863, DOI: doi:10.1016/j.talanta.2007.12.040 *
TSAY, M. JAMES ET AL.: "Singlet Oxygen Production by Peptide-Coated Quantum Dot- Photosensitizer Conjugates.", J. AM. CHEM. SOC., vol. 129, 2007, pages 6865 - 6871 *

Also Published As

Publication number Publication date
KR101288460B1 (en) 2013-07-26
KR20110000524A (en) 2011-01-03
WO2010151074A2 (en) 2010-12-29

Similar Documents

Publication Publication Date Title
WO2010151074A3 (en) Photosensitizer containing conjugates of quantum dot-chlorine derivatives and composition for treating and diagnosing cancer containing same for photodynamic therapy
MX2013012253A (en) Novel binder-drug conjugates (adcs) and their use.
CY1118061T1 (en) HETEROCYCLYL BICYCLE DERIVATIVES AS KINASE FGFR FOR THERAPEUTIC USE
IL245889B (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2011013306A (en) Tetracyclic compound.
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
IN2012DN02081A (en)
WO2011082267A3 (en) Substituted triazolo-pyrazine compounds
EP2331520A4 (en) Rosamine derivatives as agents for the treatment of cancer
PH12015500252A1 (en) Niclosamide for the treatment of solid tumors
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
WO2009095261A3 (en) Vaccine compositions
WO2012040105A3 (en) Renilla/gaussia transfected cells as a light source for in-situ photodynamic therapy of cancer
BR112012019302A2 (en) imidazo [1,2-b] [1,2,4] triazines as c-met inhibitors
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
MX2012013879A (en) Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases.
WO2012061413A3 (en) Isoflavonoid compositions and methods for the treatment of cancer
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
GB0706335D0 (en) Porphyrin compounds
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
AU2013357030A8 (en) Chlorin derivative useful in photodynamic therapy and diagnosis
WO2009088992A3 (en) Ribonuclease and thiazolidinedione compounds and their use in methods to treat cancer
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
BR112014031556A2 (en) bendamustine derivatives and related compounds, and their medical use in cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10792356

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06.03.2012)

122 Ep: pct application non-entry in european phase

Ref document number: 10792356

Country of ref document: EP

Kind code of ref document: A2